NO20001200L - Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase - Google Patents

Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase

Info

Publication number
NO20001200L
NO20001200L NO20001200A NO20001200A NO20001200L NO 20001200 L NO20001200 L NO 20001200L NO 20001200 A NO20001200 A NO 20001200A NO 20001200 A NO20001200 A NO 20001200A NO 20001200 L NO20001200 L NO 20001200L
Authority
NO
Norway
Prior art keywords
inhibitors
neutrophil elastase
pyrrolopyrrolone
derivatives
pyrrolopyrrolone derivatives
Prior art date
Application number
NO20001200A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001200D0 (no
Inventor
Michael Dennis Dowle
Harry Finch
Lee Andrew Harrison
Graham George Adam Inglis
Martin Redpath Johnson
Simon John Fawcett Macdonald
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20001200D0 publication Critical patent/NO20001200D0/no
Publication of NO20001200L publication Critical patent/NO20001200L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20001200A 1997-09-09 2000-03-08 Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase NO20001200L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9719187.8A GB9719187D0 (en) 1997-09-09 1997-09-09 Compounds
PCT/EP1998/005604 WO1999012931A1 (fr) 1997-09-09 1998-09-07 Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase

Publications (2)

Publication Number Publication Date
NO20001200D0 NO20001200D0 (no) 2000-03-08
NO20001200L true NO20001200L (no) 2000-05-08

Family

ID=10818820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001200A NO20001200L (no) 1997-09-09 2000-03-08 Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase

Country Status (24)

Country Link
US (1) US6228853B1 (fr)
EP (1) EP1019406A1 (fr)
JP (1) JP2001515902A (fr)
KR (1) KR20010023830A (fr)
CN (1) CN1278821A (fr)
AP (1) AP2000001760A0 (fr)
AU (1) AU9536098A (fr)
BR (1) BR9811651A (fr)
CA (1) CA2303249A1 (fr)
EA (1) EA200000205A1 (fr)
EE (1) EE200000137A (fr)
GB (1) GB9719187D0 (fr)
HR (1) HRP20000136A2 (fr)
HU (1) HUP0003475A3 (fr)
ID (1) ID24364A (fr)
IL (1) IL134935A0 (fr)
IS (1) IS5394A (fr)
MA (1) MA26544A1 (fr)
NO (1) NO20001200L (fr)
PL (1) PL339186A1 (fr)
SK (1) SK3242000A3 (fr)
TR (1) TR200001026T2 (fr)
WO (1) WO1999012931A1 (fr)
ZA (1) ZA988162B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
US7972868B2 (en) 2007-11-28 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
US7977117B2 (en) 2009-12-03 2011-07-12 Quest Diagnostics Investments Incorprated Vitamin D metabolite determination utilizing mass spectrometry following derivatization
US20110240840A1 (en) 2009-12-11 2011-10-06 Quest Diagnostics Investments Incorporated Mass spectrometric determination of cookson-derivatized, non-metabolized vitamin d
CA2783708C (fr) 2009-12-11 2018-09-18 Quest Diagnostics Investments Incorporated Spectrometrie de masse de composes steroidiens dans des echantillons multiplexes
BR112022004861A2 (pt) 2019-09-17 2022-06-07 Univ Duke Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
SI4106757T1 (sl) 2020-04-16 2023-11-30 Mereo Biopharma 4 Limited Postopki, ki vključujejo zaviralec nevtrofilne elastaze alvelestat, za zdravljenje bolezni dihal, ki jo sproži pomanjkanje antitripsina alfa-1
IL312002A (en) 2021-10-20 2024-06-01 Mereo Biopharma 4 Ltd Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
GB8512230D0 (en) 1985-05-14 1985-06-19 Shell Internationale Researche Preparation of carboxylic acid salt
GB9211783D0 (en) 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
CZ212498A3 (cs) 1996-01-03 1998-12-16 Smithkline Beecham P. L. C. Karbamoyloxyderiváty mutilinu, způsob výroby a farmaceutický prosředek
AR006401A1 (es) * 1996-03-28 1999-08-25 Glaxo Group Ltd Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.

Also Published As

Publication number Publication date
HRP20000136A2 (en) 2000-08-31
ZA988162B (en) 2000-03-22
AP2000001760A0 (en) 2000-03-31
IS5394A (is) 2000-03-03
HUP0003475A3 (en) 2002-01-28
ID24364A (id) 2000-07-13
US6228853B1 (en) 2001-05-08
CN1278821A (zh) 2001-01-03
EA200000205A1 (ru) 2000-10-30
EP1019406A1 (fr) 2000-07-19
BR9811651A (pt) 2000-08-08
GB9719187D0 (en) 1997-11-12
EE200000137A (et) 2001-02-15
MA26544A1 (fr) 2004-12-20
AU9536098A (en) 1999-03-29
PL339186A1 (en) 2000-12-04
IL134935A0 (en) 2001-05-20
SK3242000A3 (en) 2001-03-12
NO20001200D0 (no) 2000-03-08
JP2001515902A (ja) 2001-09-25
HUP0003475A2 (hu) 2001-09-28
CA2303249A1 (fr) 1999-03-18
KR20010023830A (ko) 2001-03-26
WO1999012931A1 (fr) 1999-03-18
TR200001026T2 (tr) 2000-09-21

Similar Documents

Publication Publication Date Title
CA2216796A1 (fr) Derives de quinazoline
WO2004024081A3 (fr) Acetyle 2-hydroxy-1,3 diaminoalcanes
DK0766670T3 (da) Tri-substituerede phenylderivater anvendelige som PDE IV inhibitorer
ATE306261T1 (de) Antithrombosemittel
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
IL133623A0 (en) Antithrombotic agents
CA2319005A1 (fr) Derives 2-pyridylmethylamine utiles en tant que fongicides
CA2268484A1 (fr) Derives d'acide hydroxamique aryloxyarylsulfonylamino de cyclobutyle
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
NO996108L (no) 9-oksinerytromycinderivater
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2001003685A3 (fr) Nouveaux promedicaments pour amidines antimicrobiennes
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
SE9803518D0 (sv) Novel compounds
NO20001198L (no) Pyrrolopyrrolondervater som inhibitorer av nøytrofil elastase
NO20001200L (no) Pyrrolopyrrolonderivater som inhibitorer av nøyrofil elastase
NO981393L (no) Guanidinoproteasehemmere
CA2309474A1 (fr) Nouveaux derives de 4-arylpiperidine pour le traitement du prurit
CA2192786A1 (fr) Inhibiteurs de molecules d'adherence, du type cyclopeptolide
AU5390900A (en) Potassium channel blocking agents
NO994131L (no) Fremgangsmaate for fremstilling av benzotiazolonforbindelser
MY133601A (en) Hydroxamic acid derivative as inhibitor of the formation of soluble human cd23
TNSN05067A1 (en) Acetyl 2-hydroxy- 1,3 diaminoalkanes
CA2187402A1 (fr) Derives de la quinoxaline pour le traitement des acouphenes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application